Gore Range Capital

Gore Range Capital is a venture capital firm focused on hands-on investing in early-stage healthcare businesses. We invest in companies that have strong potential for growth, high barriers to entry, and exceptional management teams. Our approach is simple: we invest in what we know. Over the course of our respective careers the Gore Range team has built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital we are channeling our capabilities to focus on our largest organ and the most visible manifestation of who we are - the skin. At Gore Range, we blend the hands-on approach of operationally focused private equity with the early-stage guidance needed in venture capital. We offer not just capital, but insights as well as operational, clinical, and scientific expertise while leveraging our deep industry relationships to position our portfolio companies for success.

Humberto Antunes

Partner

Debernardis, Frank

Operating Partner

Chidi Nwankpa

Principal

11 past transactions

Eirion Therapeutics

Series A in 2021
Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. The company currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to also pursue additional indications that address other major unmet clinical needs for physicians and their patients.

Dorsata

Series A in 2020
Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Paradigm Diagnostics

Series B in 2019
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

CoreMedica Laboratories

Venture Round in 2019
CoreMedica provides micro and dried blood collection and analysis tools and services. All sample testing is completed in its CAP accredited and CLIA certified laboratory in Missouri.

xMD Diagnostics

Series A in 2018
xMD Diagnostics operates in the healthcare industry focusing on biotechnology business. The company was formerly known as Bay Resources Development Group. The company is headquartered in Annapolis, Maryland. xMD Diagnostics uses high-throughput microdissection technology for the diagnosis of cancer.

Claret Medical

Series C in 2017
Claret Medical, Inc. develops a series of cerebral vascular protection systems for transcatheter aortic valve implantation, surgical, and other interventional procedures. The company’s products include Claret Medical Montage, a dual filter system and percutaneously delivered embolic protection device to capture and remove debris disloged during vascular procedures; and small (6F) catheters that are inserted into the patient's right arm to protect the patient’s brain during interventional procedures where embolic debris might be released. It offers its products for use as an embolic protection system to capture and remove embolic material (thrombus/debris) that may enter the cerebral vascular system during endovascular procedures. The company was incorporated in 2009 and is based in Santa Rosa, California.

Medikly

Convertible Note in 2016
Medikly helps pharma brands better reach, engage and understand physicians. They empower pharma to develop deeper relationships with physicians by connecting to them on an individual level.

Conversa Health

Seed Round in 2016
Conversa enables health systems to virtually engage, monitor and manage patients for chronic care, acute discharge, perioperative, oncology, OBGYN, prevention and wellness, and more. The automated care platform engages patients at high frequency and scale, while triaging to care venues when necessary, optimizing and improving the use of telehealth e-visits, phone calls and in-person consults. Conversa’s suite of COVID-19 Virtual Care Programs is being used by innovative organizations like UCSF Health, Northwell, UNC Health, Prisma Health and University Hospitals to provide symptom checking and triage, provide check-ins with quarantined patients, deliver lab results and screen employees, patients and visitors.

NovaScan

Seed Round in 2016
Founded by the former Dean of the Engineering school of the University of Wisconsin Milwaukee, NovaScan has developed and is committed to commercializing its breakthrough technology for cancer detection – solutions that require no capital equipment, are not constrained by size, provide instantaneous results, and unmatched accuracy.

Dorsata

Seed Round in 2016
Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Castle Biosciences

Series F in 2015
Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. The DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity. Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.